CAMBRIDGE, Mass., Oct. 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective October 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 3,655 shares of its common stock and an aggregate of 1,827 restricted stock units (RSUs) to four new employees under Blueprint Medicines' 2020 Inducement Plan.
Read more at prnewswire.com
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
